T he farm is considered the front line of food system security, and biosecurity practices such as disease testing are the primary means to protect the farm. Attention to on-farm biosecurity for livestock has been spurred by current certification and eradication programs for Johne's disease and bovine viral diarrhea virus (BVDV), the foot-and-mouth-disease outbreak in British sheep and cattle in 2001, and the letter-borne anthrax bioterrorism attacks in 2001 (Sandvik 2004; Sockett 1996; US Senate 2006) .
The dairy industry in the United
States has not widely adopted biosecurity practices, particularly those related to purchased cattle. In Wisconsin, less than 50% of producers with recently purchased cattle asked about the herd of origin's disease status, and less than 20% did any testing of animals they purchased (Hoe and Ruegg 2006) . In Idaho, 80% of herds undergoing expansion did not require health testing for new cattle, except for mastitis detection (Dalton et al. 2005a ). In addition, only about 40% of producers purchasing bulls quarantined them on arrival and only about 25% required a breeding soundness examination (Dalton et al. 2005b) . In the upper Midwest, nearly 60% of herds undergoing expansion obtained cattle with minimal health histories, and less than half required any health testing (Faust et al. 2001 ). Yet owners and managers involved in herd expansions indicated that herd health was compromised as a result of expansion. Similarly, Canadian farms that purchased replacement animals had more cattle testing positive for Johne's disease than farms that did not purchase animals (Chi et al. 2002) .
There are approximately 1.7 million head of dairy cattle in California, which produced about 41 billion pounds of milk in 2007, generating an estimated $61.4 billion in economic activity in the state. The movement of dairy cattle into California is a risk to the state's herds. The state imports approximately 120,000 to 130,000 head of dairy cattle annually from other states and countries, a rate of about 10,000 to 13,000 animals per month. Although this includes mature cows and bulls, the trade is primarily in Holstein and Jersey heifers or young stock (6 to 24 months old). Each year, California imports heifers from as many as 35 states and from as far away as New Hampshire (M. Ashcroft, 
Dairy farm biosecurity
Good management practices for biosecurity focus on efforts to prevent the entry of diseases onto the farm as well as to prevent disease transmission within the farm (see box) (Buhman et al. 2000) . An important element is the pre-purchase evaluation of cattle, because standard diagnostic laboratory tests or clinical examinations can detect many agents associated with clinical disease outbreaks that could 
Biosecurity practices recommended for cattle premises
• Know the health history of herds from which cattle are purchased.
• Know the health status of animals purchased or brought into the operation.
• Request that the herd veterinarian talk to the seller's veterinarian prior to purchasing animals.
• Never purchase unvaccinated animals.
• Never buy animals from a herd that has mixed-origin cattle.
• Transport animals in clean vehicles.
• Have a control program for outside animals that could spread disease (rodents, etc.).
• Load and unload animals and supplies in areas located at the perimeter of the operation.
• Provide an isolated pickup area for rendering trucks to pick up mortality, to prevent contamination of the operation.
• Limit the number of visitors who have access to cattle pens, feed mixing and storage areas, and treatment areas.
• Keep a record of visitors to the operation.
Adapted from Buhman et al. 2000 . 
Pre-purchase survey
Dairy farms enrolled in the study came from four California counties (Fresno, Kings, Stanislaus and Tulare) and were a convenience sample (not randomly selected) selected by UCCE farm advisors and practicing veterinarians. Eligible producers had to be actively engaged in purchasing animals and expect to purchase animals within 30 days of agreeing to participate in the survey. The herd owner completed a pre-purchase survey provided by the extension advisor or herd veterinarian. Survey questions focused on cattle purchased in the previous year, purchasing practices, disease testing, the examination of purchased cattle and the disposition of animals with specific disease conditions.
Seven dairy herds were enrolled, and all producers had purchased lactating animals the previous year. Five of the seven producers brought in new bulls and three bought bred (pregnant) heifers. None had information about specific disease history. Five of the producers knew the herd of origin but no testing was done. The exceptions were one producer who tested for Johne's disease, and four producers who checked for foot warts (digital dermatitis). Of the five farms purchasing bulls, two had breeding soundness exams done.
Five producers reported that they never isolate purchased animals upon arrival to the farm. Five producers did not cull animals positive for BVDV persistent infection or Johne's disease, but four usually culled cows positive for S. aureus mastitis.
Testing newly purchased cattle
The sample size for the number of cattle to be tested was based on an estimate of 120,000 animals purchased annually in California per 1.7 million head in the state dairy herd, or about 7.0% (CDFA 2005) . If owners of the approximately 820,000 dairy cattle in the four-county study area refl ect state trends, they purchase approximately 54,000 cattle per year. Detecting a 1.0% prevalence of the targeted diseases in these newly purchased cattle with 95% confi dence would require a sample size of 298 animals. An extra 25% was added in case some cattle could not be found or subsequently tested, making a total of 372 animals to test and examine in the four-county area.
All new arrivals were examined by the project investigation team or herd veterinarian within 7 days of arrival. All cows, bulls and heifers received a general physical, and bulls also received a palpation examination of scrotal contents and seminal vesicles. A blood sample was obtained for the following infectious disease tests: BVDV antigen-capture ELISA (enzyme-linked immunosorbent assay), BLV antibody ELISA and, for cattle over 2 years of age, Johne's disease antibody-capture ELISA. Blood samples were processed by the California Animal Health and Food Safety Laboratory in Tulare. Milk samples from each quarter were obtained from all cows and post-calving heifers, and evaluated for common contagious mastitis pathogens (including S. aureus, S. agalactiae and Mycoplasma spp.) and for "environmental" pathogens like E. coli and Streptococcus species, by the UC Davis Veterinary Medicine Teaching and Research Center's Milk Quality Laboratory in Tulare. Fecal samples were evaluated for the presence of Salmonella.
Within the fi rst week of arrival to participating farms, 382 dairy cattle were examined and tested. Of these, 25% were pre-calving heifers, 65% were lactating cows and 10% were bulls. Most of the cattle (72.8%) came from private owner sales and the rest through a sales yard, cattle buyer or auction. In addition, 57% of the cattle had U.S. Department of Agriculture (USDA) ear tags placed in California, 21% had ear tags from other states (Hawaii, Minnesota, North Dakota, South Dakota, Colorado, Washington and Oregon) and 22% had no offi cial USDA ear tag.
The most common fi nding was evidence of BLV infection (33%) (table 1). Only one bull was BLV test-positive but over 35% of the cows and heifers were, making them 13 times more likely to test positive for this disease than bulls (P < 0.001). The proportion of BLV-positive purchased animals varied by destination farm, and ranged from 7% to 80%. Of 38 bulls evaluated, one was cryptorchid (right testicle not descended) and fi ve had fi rm swellings of either a seminal vesicle or epididymus, parts of the male reproductive tract. Swellings in these structures can indicate previous or current infl ammation that could impair fertility.
Producer reactions to tests
Participating producers received a standard report of the physical examination fi ndings and laboratory results. A questionnaire, provided within 2 weeks of sampling, captured producer decisions for each test-positive animal: (1) marked the cow/heifer with, for example, a leg band and kept her in the herd; (2) kept her but moved or will move her to a separate string for cows with that kind of infection; (3) removed the cow/heifer from the herd; (4) treated the cow/heifer; or (5) have not yet decided what to do with the animal(s). The questionnaire also asked producers whether they would have purchased the animal had they known the test results beforehand.
When provided with test-positive results, most producers indicated that they would keep the animals in the herds rather than cull but would not have purchased the cow had they known that she had the disease. For the Decisions regarding BLV-positive animals were producer-specific. Each producer reported making the same decision for each of the animals testing positive for any condition in their herds (table 3) . Five of the seven producers would not have purchased test-positive animals if they had known they were infected. The producer with affected bulls decided to remove all these animals from his herd, would not have purchased them knowing they were affected, and would make his own decisions about what to do with them.
Making biosecurity decisions
In this pilot study, decision-making by dairy producers varied. Knowing infection status before purchasing can provide information for decisions about treatment, isolation or culling, but the participating producers had different levels of risk-tolerance and said they would seek veterinary advice to varying degrees. Even though these producers were regularly purchasing animals and may have had infectious diseases in their herds in the past, these factors did not appear to influence their decision to require testing. In addition, new cattle were rarely isolated or quarantined: only two of the seven producers isolated some new additions on arrival, confirming the results of previous surveys (Buttars et al. 2006; Dalton et al. 2005a; Faust et al. 2001; Hoe and Ruegg 2006) .
The perception of risk among farmers does not always translate into risktolerant or risk-averse behavior. In a study of swine producers, the perceived importance of a biosecurity practice was not necessarily associated with its implementation (Casal et al. 2007 ). The swine producers were more likely to implement biosecurity measures that affected disease transmission through people and wildlife than to implement measures for the most important risk for disease transmission: incoming replacement animals.
Costs and benefits of testing
The cost of examination and testing is a likely deterrent to producers purchasing large groups of animals. However, If the farm strategy is to keep S. aureus intramammary infections out of a herd and the probability of infection is 0.8%, the cost of milk cultures to find one infected cow in 100 is about $625. This is less than the cost of the average purchased cow minus her salvage value if she is tested after purchase (about $1,800 and $400 to $500, respectively). If the bacteria spreads and infects other cows, the costs due to clinical mastitis could average about 726 pounds (330 kilograms) of milk per lactation, about $120 (Shim et al. 2004 ).
Bovine leukosis virus. Evidence of BLV infection was the most common finding in our study. The consequences of BLV infection can include immunosuppression, premature culling, loss of salvage value if the animal becomes clinical and is culled, higher calving intervals and lower milk production (D' Angelino et al. 1998; Ott et al. 2003; Pollari et al. 1992 Pollari et al. , 1993 . A few studies have found no influence of BLV infection on herd performance (Heald et al. 1992; Tiwari et al. 2007 ). However, a recent study that controlled for other factors associated with milk production found a significant relationship between higher herd prevalence of BLV and lower milk production and annual value of production (a combination of milk production and annual value of calves at birth, minus the annual net replacement cost) (Ott et al. 2003) . Given Ott's model, a herd with a BLV prevalence of 33% has 253 pounds (115 kilograms) less milk per cow in the herd (1% lower production compared to cows in herds without BLV). BLV infects lymphocytes, resulting in a lifelong infection, and can result in lymphosarcoma or malignant lymphoma. If 0.1% to 5.0% of BLV-positive animals develop lymphosarcoma and the herd prevalence of BLV is 33%, as many as 1% of animals in the herd will be culled prematurely due to the development of lymphosarcoma (Pelzer 1997) . Premature culling incurs losses due to the replacement of a cow with a heifer, loss of pregnant cows and loss of the cow's market value (Rhodes et al. 2003) . Nationwide, 5,175,861 beef and dairy cows were sent to market in 2002 (USDA 2008). Of those, 2.77% (143,484) were condemned, and 17% (25,075) of those condemnations were for malignant lymphoma, resulting in no value to the producer or packer.
The laboratory cost for a BLV test is about $8.70 for 10 samples. In the case of BLV infections from purchased cattle, the risk is real and the potential consequences significant. Thus, BLV test results should be considered in dairycattle purchasing decisions.
Johne's disease. Only one Johne's disease test-positive animal was found in our study, resulting in less than 1% prevalence. However, the sensitivity of tests for this disease is notoriously low (Collins et al. 2006) . The ELISA test on serum has a sensitivity of about 30% to 50%, which is the probability that a test is positive given that the animal is truly infected (Collins et al. 2006) . As such, a negative Johne's disease test does not necessarily mean "not infected. " Collins et al. (2006) provided a cattle purchase flowchart for Johne's disease biosecurity, which showed that the highest risk for buying infected cattle is from untested herd replacements.
The costs of Johne's-positive herds include reduced milk yield, body weight losses, a reduction in market cow beef value and early culling. About $60 to $90 of income per cow is lost in Johne's-positive herds compared to negative herds (Collins et al. 2006; Ott et al. 1999 ). The prevalence of Johne'sinfected dairy cattle is estimated to be about 22% nationwide, but it varies by region (table 4) (Ott et al. 1999) .
Although the West appears to have a relatively low proportion of Johne'spositive herds, buying replacement animals can put Western dairies at risk for introducing the disease. Laboratory tests for this disease are about $3.60 for one and $5.50 for 10 samples.
Bull diseases. Replacement bulls can bring in disease as well as be poor performers. If it costs $50 to sample, test and conduct a 5-minute reproductive exam on a single bull, the 38 bulls in our project represented a total testing cost of $1,900, or about the value of one bull. With one cryptorchid bull and five bulls with evidence of reproductive tract problems that could affect fertility, the testing cost can be justified. Adding a test (about $8 each) for trichomoniasis, a disease spread venereally that can affect cow fertility, would also be an important biosecurity measure.
Testing as an insurance policy
Decisions to test cattle purchases for infectious diseases depend on both the risk of disease introduction and the risk aversion (or tolerance) level of each producer. Just as with making a decision about purchasing an insurance policy, individuals decide whether they can absorb the costs of some negative event or if they want to minimize risks associated with infectious diseases. Producers who decide not to test incoming cattle can employ three other strategies: (1) ask about the herd of origin and any disease information the sellers have, which will still not address carrier animals; (2) carefully examine cattle, particularly breeding bulls, to detect any obvious abnormalities before purchasing; and (3) provide an isolation facility where purchased animals can become acclimated to new surroundings and visually screened for abnormalities or illness for up to 3 weeks before adding them to the herd. These latter recommendations may help reduce the risk of disease introduction and would be first steps to help secure the herd's health. It would Testing strategies for pre-or post-purchase of dairy herd replacements All (bulls, cows, heifers)
• Examination for foot warts • Blood sample for Johne's ELISA test (if over 2 years of age)
• Ear notch or blood sample for BVDV persistent infection test
• Fecal sample for Salmonella culture
• Blood sample for bovine leukosis virus (BLV) antigencapture ELISA
Bulls only
• Breeding soundness investigation, including palpation of scrotal contents and seminal vesicles
• Preputial sample for Tritrichomonas testing
Cows only
• Milk sample for mastitispathogen culture be prudent for producers to develop a protocol for testing risky animals when the herd of origin is unknown or health history is lacking. Our results indicate that there are opportunities for dairy advisors, herd veterinarians and extension educators to emphasize the risks associated with new herd members and to work with clients on appropriate purchasing and testing strategies. Specifically, they can help producers to: (1) understand the consequences of specific infections, (2) identify and prioritize specific diseases they want to keep out of their herds, (3) assess existing disease conditions in their operation, (4) develop a testing plan for risky animals before or after purchasing (using table 4 and box below), (5) make the best decisions on what to do with infected animals based on available information and (6) assess the operation and facilities for potential within-herd transmission of diseases (CFSPH 2008) . Keeping infectious diseases and other cattle conditions out of the herd can save money in the future.
